Design, Synthesis, and Biological Evaluation of 2-Aminothiazole Derivatives as Novel Checkpoint Kinase 1 (CHK1) Inhibitors

被引:4
|
作者
Deng, Minjie [1 ]
Wang, Peipei [2 ]
Long, Xiubing [3 ]
Xu, Gaoya [2 ]
Wang, Chang [5 ]
Li, Jia [2 ,5 ,6 ]
Zhou, Yubo [2 ,4 ,5 ]
Liu, Tao [1 ,7 ]
机构
[1] Zhejiang Univ, Coll Pharmaceut Sci, ENS Joint Lab Med Chem, ZJU, Hangzhou 310058, Peoples R China
[2] Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China
[3] Wuxi Apptec Co Ltd, 288 Fute Zhong Rd, Shanghai 200131, Peoples R China
[4] Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan 528400, Peoples R China
[5] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
[6] Bohai Rim Adv Res Inst Drug Discovery, Shandong Lab Yantai Drug Discovery, Yantai 264117, Peoples R China
[7] Zhejiang Univ, Hangzhou Inst Innovat Med, Inst Drug Discovery & Design, Hangzhou 310058, Peoples R China
基金
中国国家自然科学基金;
关键词
2-aminothiazole; CHK1; inhibitors; antiproliferation; hematologic malignancies; biological activity;
D O I
10.1002/cmdc.202200664
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of 2-aminothiazole derivatives were designed, synthesized on the basis of bioisosterism strategy and evaluated for their CHK1 inhibitory activity. Most of them exhibited potent CHK1 inhibition, and excellent antiproliferative activity against MV-4-11 and Z-138 cell lines. Systematic structure-activity relationship (SAR) efforts led to the discovery of a promising compound 8 n, which showed potent CHK1 inhibitory activity with IC50 value of 4.25 +/- 0.10 nM, excellent antiproliferative activity against MV-4-11 and Z-138 cells with IC50 value of 42.10 +/- 5.77 nM and 24.16 +/- 6.67 nM, respectively, as well as moderate oral exposure (AUC((0-t))=1076.25 h center dot ng/mL) in mice. Additionally, treatment of MV-4-11 cells with compound 8 n for 2 h led to robust inhibition of CHK1 autophosphorylation on serine 296. Furthermore, kinase selectivity assay revealed that 8 n displayed acceptable selectivity toward 15 kinases. These results demonstrated that compound 8 n may be a promising potential anticancer agent for further development.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Design, synthesis and evaluation of novel thienopyridazine derivatives as Chk1/2 inhibitors
    Shen, Dadong
    Liu, Hanyu
    Qian, Feng
    Wang, Pu
    BIOORGANIC CHEMISTRY, 2022, 121
  • [2] Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors
    Vogt, Dominik
    Weber, Julia
    Ihlefeld, Katja
    Brueggerhoff, Astrid
    Proschak, Ewgenij
    Stark, Holger
    BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (19) : 5354 - 5367
  • [3] Design, synthesis and biological evaluation of thienopyridinones as Chk1 inhibitors
    Song, Pinrao
    Peng, Peng
    Han, Mengmeng
    Cao, Xianchao
    Ma, Xiaodong
    Liu, Tao
    Zhou, Yubo
    Hu, Yongzhou
    BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (17) : 4882 - 4892
  • [4] Synthesis of selenophene derivatives as novel CHK1 inhibitors
    Hong, Pao-Chiung
    Chen, Li-Jung
    Lai, Tzu-Yun
    Yang, Huei-Yu
    Chiang, Shih-Jan
    Lu, Yann-Yu
    Tsai, Ping-Kuei
    Hsu, Hung-Yi
    Wei, Win-Yin
    Liao, Chu-Bin
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (17) : 5065 - 5068
  • [5] Synthesis and evaluation of substituted benzoisoquinolinones as potent inhibitors of Chk1 kinase
    Garbaccio, Robert M.
    Huang, Shaei
    Tasber, Edward S.
    Fraley, Mark E.
    Yan, Youwei
    Munshi, Sanjeev
    Ikuta, Mari
    Kuo, Lawrence
    Kreatsoulas, Constanine
    Stirdivant, Steve
    Drakas, Bob
    Rickert, Keith
    Walsh, Eileen S.
    Hamilton, Kelly A.
    Buser, Carolyn A.
    Hardwick, James
    Mao, Xianzhi
    Beck, Stephen C.
    Abrams, Marc T.
    Tao, Weikang
    Lobell, Rob
    Sepp-Lorenzino, Laura
    Hartman, George D.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (22) : 6280 - 6285
  • [6] Synthesis and development of potent Chk1 kinase inhibitors
    Huang, Shaei
    Garbaccio, Rob
    Tasber, Edward S.
    Fraley, Mark E.
    Steen, Justin T.
    Yan, Youwei
    Munshi, Sanjieev
    Ikuta, Mari
    Kuo, Lawrence
    Kreatsoulas, Constantine
    Reilly, Michael
    Mahan, Elizabeth
    Stirdivant, Steve
    Drakas, Bob
    Rickert, Keith
    Walsh, Eileen
    Hamilton, Kelly
    Buser, Carolyn A.
    Hardwick, James
    Mao, Xianzhi
    Beck, Steve
    Abrams, Marc
    Tao, Weikang
    Lobell, Rob
    Sepp-Lorenzino, Laura
    Hartman, George D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [7] Synthesis and biological evaluation of 2-aminothiazole derivatives as antimycobacterial and antiplasmodial agents
    Mjambili, Faith
    Njoroge, Mathew
    Naran, Krupa
    De Kock, Carmen
    Smith, Peter J.
    Mizrahi, Valerie
    Warner, Digby
    Chibale, Kelly
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (02) : 560 - 564
  • [8] Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors
    Lee, Ju-Hee
    Choy, Megan L.
    Ngo, Lang
    Venta-Perez, Gisela
    Marks, Paul A.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (49) : 19629 - 19634
  • [9] MEDI 128-Structure-based design, synthesis and biological evaluation of macrocyclic Chk1 Inhibitors
    Tao, Zhi-Fu
    Wang, Le
    Tong, Yunsong
    Li, Gaoquan
    Przytulinska, Magdalena
    Sullivan, Gerard
    Chen, Zehan
    Xiao, Zhan
    Gu, Wendy
    Xue, John
    Bui, Mai-Ha
    Merta, Philip
    Kovar, Peter
    Zhang, Haiying
    Park, Chang
    Stewart, Kent D.
    Sham, Hing L.
    Sowin, Thomas
    Rosenberg, Saul H.
    Lin, Nan-Horng
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
  • [10] Targeting the checkpoint kinase Chk1 in cancer therapy
    Merry, Callie
    Fu, Kang
    Wang, Jingna
    Yeh, I-Ju
    Zhang, Youwei
    CELL CYCLE, 2010, 9 (02) : 279 - 283